63 results on '"Ljungman, Per"'
Search Results
2. Celebrating the registration of 9.000 patients treated with CAR T cells in the EBMT registry: Collection of real-world data in the context of hematopoietic cellular therapies.
- Author
-
Chabannon, Christian, Ruggeri, Annalisa, Montoto, Silvia, van Biezen, Anja, van der Werf, Steffie, Markslag, Annemiek, Sanchez-Ortega, Isabel, Camara, Rafael de la, Ljungman, Per, Mohty, Mohamad, Kröger, Nicolaus, Sureda, Ana, McGrath, Eoin, Bonini, Chiara, and Kuball, Jurgen
- Abstract
The European society for Blood and Marrow Transplantation (EBMT) has a long-standing interest in the evaluation of hematopoietic cell transplantation. More than three decades ago, its members established a continental registry. Today, more than 700,000 patients have been registered, and information has been gathered on more than 800,000 transplants. This huge amount of information has allowed conducting multiple retrospective studies, evaluating changes in practices over time and for different categories of diseases, benchmarking outcome across EBMT affiliated centers, and increasingly serves to build synthetic comparators to evaluate the introduction of therapeutic innovations in the field of hematology. CAR-T cells therapies draw on human and technical resources that are also used to deliver HCT; they elicit side effects that require the implementation of risk mitigation plans; they are living drugs that persist in the body of the recipient and thus deserve prolonged follow-up; the introduction of CAR-T cells in the pharmacopeia is likely to significantly impact on the practice of BMT; for all these reasons and even before the first approvals of CAR-T Cells in Europe, EBMT engaged in a project aiming at complementing the EBMT Registry with a Cellular Therapy Form, with the objective to register CAR-T cells treated patients and collect information on their short-, middle- and long-term outcome. The goal is to provide EBMT investigators with a tool for primary analyses of the collected information and to support secondary use of data transferred at the individual level to Marketing Authorization Holders and other interested parties, to fulfill their obligations to health authorities and further evaluate the actual medical values of CAR-T Cells in different contexts and indications. The EBMT Registry received a positive opinion from the European Medicines agency in 2019, and five years later contains information on more than 9.000 treated patients. This article describes the journey to start this new activity, lessons to be drawn in view of improving the collection of real-world data, and what existing information tells us in terms of patient access. • Advanced Therapy Medicinal Products deserve peculiar attention in terms of follow-up after market approval. • CAR-T cells are the most widely used advanced therapies, since the first approvals in 2017 in the USA and 2018 in Europe. • Maintenance of clinical benefit in diverse patient populations requires additional demonstration through analyses of real-world data. • The EBMT has built new tools to survey the field of CAR-T Cells. • Establishing a European CAR-T Cells Registry meant addressing internal and external challenges. • Patients have been registered since 2019 in the EBMT Registry, in the year following the approval of the first two products by the European Medicines Agency (EBMT), and are now totaling more than 9.000 individuals. • A formal process is in place through the GoCART coalition to periodically revise the nature and format of data to be reported, and upgrade the quality of the information contained in the Registry, while considering our fast improving knowledge of this emerging field. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients - Study of infectious diseases working party of EBMT.
- Author
-
Mikulska, Malgorzata, Knelange, Nina, Nicolini, Laura Ambra, Tridello, Gloria, Santarone, Stella, Di Bartolomeo, Paolo, de la Camara, Rafael, Cuéllar, Clara, Velardi, Andrea, Perruccio, Katia, Ljungman, Per, Zaucha, Jan, Piekarska, Agnieszka, Basak, Grzegorz, Karakulska-Prystupiuk, Ewa, Angelucci, Emanuele, Ciceri, Fabio, Lupo-Stanghellini, Maria Teresa, Fouillard, Loic, and García-Cadenas, Irene
- Subjects
PILOT projects ,COMBINATION drug therapy ,HEPATITIS C ,ANTIVIRAL agents ,HEPATITIS viruses ,TREATMENT effectiveness ,HEMATOPOIETIC stem cell transplantation ,TRANSPLANTATION of organs, tissues, etc. - Abstract
Objectives: Limited data is available on HCV directly acting agents (DAAs) in haematopoietic stem cell transplant (HSCT) recipients. This study aimed at reporting the characteristics, treatment practices and treatment efficacy in HSCT recipients with chronic HCV.Methods: Prospective observational study from EBMT Infectious Diseases Working Party (IDWP). Patients with chronic HCV infection were included.Results: Between 12/2015 and 07/2018, 45 patients were included: male in 53%; median age 49 years (range, 8-75); acute leukaemia in 48.9%, lymphoma in 17.7%, non-malignant disorders in 22.3%; allogeneic HSCT in 84%; 77.8% no immunosuppressive treatment. Genotypes 1, 2, 3 and 4 were detected in 54.5%, 20.5%, 13.6% and 11.4%, respectively; advanced fibrosis in 40%, including cirrhosis in 11.4%. Overall, 37 (82.2%) patients received DAAs, at a median of 8.4 years after HSCT (16.2% within 6 months from HSCT). Sofosbuvir-based treatment was given to 62.2%. Thirty-five patients completed planned treatment course, with sustained virological response (SVR) of 89.1%, and 94.3% (33/35) in those who completed the treatment. Side effects possibly related to DAAs were reported in 5 (14%) and did not require treatment discontinuation.Conclusions: DAAs treatment was effective, safe and feasible in this cohort of mainly allogeneic HSCT recipients with mild/moderate liver damage. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
4. Human herpesvirus-6 infection in solid organ and stem cell transplant recipients
- Author
-
Ljungman, Per and Singh, Nina
- Published
- 2006
- Full Text
- View/download PDF
5. Would monitoring CMV immune responses allow improved control of CMV in stem cell transplant patients
- Author
-
Ljungman, Per
- Published
- 2006
- Full Text
- View/download PDF
6. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogenic bone marrow transplantation
- Author
-
Prentice, H. Grant, Gluckman, Eliane, Powles, Ray L., Ljungman, Per, Milpied, Noel J., Fernandez Ranada, Jose M., Mandelli, Franco, Kho, Pearl, Kennedy, Liam, and Bell, Andrew R.
- Subjects
Cytomegalovirus infections -- Prevention ,Acyclovir -- Evaluation ,Bone marrow -- Transplantation - Published
- 1994
7. Respiratory virus infections in bone marrow transplant recipients: the European perspective
- Author
-
Ljungman, Per
- Subjects
Bone marrow -- Transplantation ,Transplantation of organs, tissues, etc. -- Complications ,Respiratory tract infections -- Complications ,Health ,Health care industry - Abstract
The role of respiratory viruses in severe complications following bone marrow transplantation was examined in a survey of selected transplant centers in Europe belonging to the European Group for Blood and Marrow Transplantation. Information was collected on 57 cases of infections with respiratory viruses, including adenoviruses. In two centers that had conducted prospective studies of bone marrow recipients with respiratory symptoms, the frequency of these infections was 7.1% and 4%, respectively. The severity of these infections varied. Pneumonias caused by respiratory syncytial virus and adenovirus were associated with mortality rates of 60% and 75%, respectively, whereas pneumonia caused by parainfluenza had a mortality rate of 20%. Influenza infections progressed to fatal pneumonia in 17% of cases. Results of antiviral therapy varied. As the results of our survey showed, respiratory virus infections are not infrequent after bone marrow transplantation and are associated with significant morbidity and mortality.
- Published
- 1997
8. Intercontinental study on pre-engraftment and post-engraftment Gram-negative rods bacteremia in hematopoietic stem cell transplantation patients: Risk factors and association with mortality.
- Author
-
Averbuch, Diana, Tridello, Gloria, Hoek, Jennifer, Mikulska, Malgorzata, Pabst, Thomas, Yaňez San Segundo, Lucrecia, Akan, Hamdi, Özçelik, Tülay, Donnini, Irene, Klyasova, Galina, Botelho de Sousa, Aida, Zuckerman, Tsila, Tecchio, Cristina, de la Camara, Rafael, Aki, Sahika Zeynep, Ljungman, Per, Gülbas, Zafer, Nicolas-Virelizier, Emmanuelle, Calore, Elisabetta, and Perruccio, Katia
- Abstract
Objectives: We present here data on Gram-negative rods bacteremia (GNRB) rates, risk factors and associated mortality.Methods: Data on GNRB episodes were prospectively collected in 65 allo-/67 auto-HSCT centers in 24 countries (Europe, Asia, Australia). In patients with and without GNRB, we compared: demography, underlying disease, HSCT-related data, center` fluoroquinolone prophylaxis (FQP) policy and accreditation status, and involvement of infection control team (ICT).Results: The GNRB cumulative incidence among 2818 allo-HSCT was: pre-engraftment (pre-eng-allo-HSCT), 8.4 (95% CI 7-9%), post-engraftment (post-eng-allo-HSCT), 5.8% (95%CI: 5-7%); among 3152 auto-HSCT, pre-eng-auto-HSCT, 6.6% (95%CI: 6-7%), post-eng-auto-HSCT, 0.7% (95%CI: 0.4-1.1%). GNRB, especially MDR, was associated with increased mortality. Multivariate analysis revealed the following GNRB risk factors: (a) pre-eng-allo-HSCT: south-eastern Europe center location, underlying diseases not at complete remission, and cord blood source; (b) post-eng-allo-HSCT: center location not in northwestern Europe; underlying non-malignant disease, not providing FQP and never accredited. (c) pre-eng-auto-HSCT: older age, autoimmune and malignant (vs. plasma cell) disease, and ICT absence.Conclusions: Benefit of FQP should be explored in prospective studies. Increased GNRB risk in auto-HSCT patients transplanted for autoimmune diseases is worrying. Infection control and being accredited are possibly protective against bacteremia. GNRB are associated with increased mortality. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
9. Humoral immunity to tetanus, diphtheria and polio in adults after treatment for hematological malignancies.
- Author
-
Einarsdottir, Sigrun, Ljungman, Per, Kaijser, Bertil, Nicklasson, Malin, Horal, Peter, Norder, Helen, Bergström, Tomas, and Brune, Mats
- Subjects
- *
HEMATOLOGIC malignancies , *POLIO , *DIPHTHERIA , *HUMORAL immunity , *TETANUS , *LYMPHOBLASTIC leukemia - Abstract
After chemotherapy, children with acute lymphocytic leukemia lose immunity and need revaccination against tetanus and diphtheria. However, little is known about immunity in adult patients after treatment for hematological malignancies. In this study, we assessed serology levels against polio, diphtheria and tetanus in adult patients after conventional treatment for leukemia and lymphoma. One hundred and four patients, age 61 (19–86) years, were included at a median of 18 (4–77) months after chemotherapy for acute leukemia (n = 24) or lymphoma (n = 80). Pre-treatment sera were available in 73 cases for a pre-versus post treatment comparison. Healthy, age- and sex matched controls were available for 47 pts. Tetanus antibodies were quantified using ELISA, and antibody levels ≥0.01 IU/mL were considered protective. Diphtheria antibodies were analyzed using neutralization test (n = 60) or by ELISA (n = 44). In both tests values ≥0.01 IU/mL were considered protective. Antibodies against poliovirus serotype 1 and 3 were assessed by a neutralizing test. A microneutralization titer of ≥2 was considered protective. Tetanus : There were significantly more non-immune patients after treatment (24%), compared to before (12%), p = 0.02. Post-treatment antibody levels were significantly lower than pre-treatment levels (p = 0.02). Diphtheria: There was a trend, p = 0.06, towards more non-immune patients after treatment (21%) compared to before (27%). Antibody levels post treatment were lower than pre treatment levels (p = 0.03) and lower than controls (p = 0.01). Polio: There was no significant difference in the number of non-immune patients before vs after chemotherapy for either PV1 or PV3. Protective immunity against serotype 1 and 3 was preserved in 90 and 97%, respectively. After standard chemotherapy for leukemia and lymphoma a significant proportion of patients had impaired humoral immunity to diphtheria and tetanus. However, polio immunity was well preserved. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).
- Author
-
Ljungman, Per, de la Camara, Rafael, Robin, Christine, Crocchiolo, Roberto, Einsele, Hermann, Hill, Joshua A, Hubacek, Petr, Navarro, David, Cordonnier, Catherine, Ward, Katherine N, and 2017 European Conference on Infections in Leukaemia group
- Subjects
- *
STEM cell transplantation , *CYTOMEGALOVIRUS diseases , *HEMATOLOGIC malignancies , *ANTIVIRAL agents , *INFECTION - Abstract
Cytomegalovirus is one of the most important infections to occur after allogeneic haematopoietic stem cell transplantation (HSCT), and an increasing number of reports indicate that cytomegalovirus is also a potentially important pathogen in patients treated with recently introduced drugs for hematological malignancies. Expert recommendations have been produced by the 2017 European Conference on Infections in Leukaemia (ECIL 7) after a review of the literature on the diagnosis and management of cytomegalovirus in patients after HSCT and in patients receiving other types of therapy for haematological malignancies. These recommendations cover diagnosis, preventive strategies such as prophylaxis and pre-emptive therapy, and management of cytomegalovirus disease. Antiviral drugs including maribavir and letermovir are in development and prospective clinical trials have recently been completed. However, management of patients with resistant or refractory cytomegalovirus infection or cytomegalovirus disease is a challenge. In this Review we summarise the reviewed literature and the recommendations of the ECIL 7 for management of cytomegalovirus in patients with haematological malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
11. Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
- Author
-
Gagelmann, Nico, Ljungman, Per, Styczynski, Jan, and Kröger, Nicolaus
- Subjects
- *
ANTIVIRAL agents , *CYTOMEGALOVIRUS disease prevention , *HEMATOPOIETIC stem cell transplantation , *ACYCLOVIR , *GANCICLOVIR , *VALACYCLOVIR , *CLINICAL trials - Abstract
Highlights • Antiviral prophylaxis significantly reduces CMV disease and infection. •. Ganciclovir and letermovir appear to be the best options for CMV outcomes. • Inconclusive results of antiviral prophylaxis and survival. • Randomized head-to-head comparisons are needed. Abstract Over the past 25 years, several randomized controlled trials have investigated the efficacy of different antiviral agents for cytomegalovirus (CMV) prophylaxis in allogeneic hematopoietic cell transplantation. We performed a systematic literature review, conventional meta-analysis, and network meta-analysis using a random-effects model and risk ratios (RRs) with corresponding 95% confidence intervals (CIs) as effect estimates. Fifteen randomized controlled trials were identified, including 7 different antiviral agents: acyclovir, ganciclovir, maribavir, brincidofovir, letermovir, valacyclovir, and vaccine. Twelve trials used placebo as comparator while 3 trials compared different antiviral agents. We found evidence for CMV disease and infection being significantly reduced by antiviral prophylaxis, with an RR of.66 (95% CI,.48 to.90) and.63 (95% CI,.50 to.79). Across the network, ganciclovir showed the best relative efficacy for CMV disease while letermovir provided first rank of being the best option for CMV infection. The risk for death was not significantly influenced by antiviral prophylaxis in the meta-analysis, with an RR of.92 (95% CI,.78 to 1.08), as well as in the network meta-analysis. In terms of safety, letermovir was at least similar in comparison with placebo and most agents while both letermovir and acyclovir showed significantly reduced risk for serious adverse events compared with ganciclovir, with RRs of.55 (95% CI,.30 to 1.00) for letermovir and.63 (95% CI,.42 to.93) for acyclovir. With a probability of 81%, letermovir appears to be the best option in terms of safety. Future randomized head-to-head comparisons are needed to evaluate the definite efficacy and safety of different prophylactic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
12. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
- Author
-
Bergh, Jonas, Wiklund, Tom, Erikstein, Bjorn, Lidbrink, Elisabet, Lindman, Henrik, Malmstrom, Per, Kellokumpu-Lehtinen, Pirkko, Bengtsson, Nils-Olof, Soderlund, Gustaf, Anker, Gun, Wist, Erik, Ottosson, Susanne, Salminen, Eeva, Ljungman, Per, Holte, Harald, Nilsson, Jonas, Blomqvist, Carl, and Wilking, Nils
- Subjects
Breast cancer -- Adjuvant treatment ,Fluorouracil -- Health aspects ,Cyclophosphamide -- Health aspects ,Drug therapy, Combination -- Usage ,Chemotherapy -- Evaluation ,Granulocyte colony-stimulating factor -- Evaluation - Published
- 2000
13. Role of intravenous dosage regimens of bisphosphonates in relation to other aetiological factors in the development of osteonecrosis of the jaws in patients with myeloma.
- Author
-
Jarnbring, Fredrik, Kashani, Ali, Björk, Andreas, Hoffman, Tobias, Krawiec, Kamilla, Ljungman, Per, and Lund, Bodil
- Subjects
INTRAVENOUS therapy ,DIPHOSPHONATES ,DRUG dosage ,JAW necrosis ,ETIOLOGY of diseases ,TUMORS ,PATIENTS - Abstract
The aim of this case-control study was to identify possible explanatory risk factors for the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) by estimating the effects of intravenous dosage regimens of bisphosphonates, coexisting diseases, and other drugs on 201 patients with multiple myeloma, with or without BRONJ. We compared sex, treatment with bisphosphonates, incidence of diabetes, and the taking of drugs such as corticosteroids and chemotherapy in patients who had BRONJ (n = 44) and patients who did not (n = 157). Among the bisphosphonates given intravenously zoledronic acid showed a stronger correlation with BRONJ than pamidronic acid. The risk of developing BRONJ increased dramatically at cumulative intravenous doses of more than 78 mg of zoledronic acid or 600 mg of pamidronic acid, which corresponds to treatment for 18 months or longer. Diabetes mellitus correlated significantly with the development of BRONJ (p = 0.01) while there was no correlation with sex, simultaneous treatment with corticosteroids, or chemotherapy. In conclusion, treatment with zoledronic acid, high doses of pamidronic acid, and the coexistence of diabetes mellitus seem to be associated with the development of BRONJ. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
14. Vaccination of immunocompromised patients.
- Author
-
Ljungman, Per
- Subjects
- *
IMMUNOCOMPROMISED patients , *VACCINATION , *COMMUNICABLE disease immunology , *IMMUNOSUPPRESSION , *IMMUNE response - Abstract
Clin Microbiol Infect 2012; 18 (Suppl. 5): 93-99 Abstract Vaccination of immunocompromised patients is challenging both regarding efficacy and safety. True efficacy data are lacking so existing recommendations are based on immune responses and safety data. Inactivated vaccines can generally be used without risk but the patients who are most at risk for infectious morbidity and mortality as a result of their severely immunosuppressed state are also those least likely to respond to vaccination. However, vaccination against pneumococci, Haemophilus influenzae and influenza are generally recommended. Live vaccines must be used with care because the risk for vaccine-associated disease exists. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
15. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial
- Author
-
Marty, Francisco M, Ljungman, Per, Papanicolaou, Genovefa A, Winston, Drew J, Chemaly, Roy F, Strasfeld, Lynne, Young, Jo-Anne H, Rodriguez, Tulio, Maertens, Johan, Schmitt, Michael, Einsele, Hermann, Ferrant, Augustin, Lipton, Jeffrey H, Villano, Stephen A, Chen, Hongzi, and Boeckh, Michael
- Subjects
- *
RANDOMIZED controlled trials , *ANTIVIRAL agents , *CYTOMEGALOVIRUS disease prevention , *HOMOGRAFTS , *STEM cell transplantation - Abstract
Summary: Background: Available drugs against cytomegalovirus have adverse effects that compromise their prophylactic use in recipients of allogeneic stem-cell transplants. We assessed the safety, tolerability, and antiviral activity of oral maribavir in such patients. Methods: In this placebo-controlled, randomised, double-blind, multicentre phase 3 study, we enrolled adult patients recipient-seropositive or donor-seropositive for cytomegalovirus who had undergone allogeneic stem-cell transplantation. Patients were recruited from 90 centres in Canada, Europe, and the USA. After engraftment, patients were stratified by recipient cytomegalovirus serostatus and conditioning regimen (myeloablative or reduced-intensity) and assigned (2:1) by masked computer-generated randomisation sequence to receive maribavir 100 mg twice daily or placebo for up to 12 weeks, with weekly blood cytomegalovirus surveillance. If the virus was detected, administration of study drug was stopped and pre-emptive anticytomegalovirus treatment started. The primary endpoint was cytomegalovirus disease within 6 months of transplantation. Analysis was by intention-to-treat. This study is registered with ClinicalTrials.gov, NCT00411645. Findings: Between December, 2006, and May, 2008, 681 patients were enrolled and assigned to receive maribavir (454) or placebo (227). The incidence of cytomegalovirus disease within 6 months was 20 of 454 (4%) for the maribavir group and 11 of 227 (5%) for the placebo group (OR 0·90; 95% CI 0·42–1·92). During the 100 days following transplantation, cytomegalovirus infection rates as measured by pp65 antigenaemia were lower in the maribavir group (26·4%) than in the placebo group (34·8%; OR 0·67; 0·47–0·95), but not when measured by plasma cytomegalovirus DNA PCR (27·8%vs 30·4%; OR 0·88; 0·62–1·25), nor by initiation of treatment against cytomegalovirus (30·6%vs 37·4%; OR 0·73, 0·52–1·03). Maribavir was well tolerated: most adverse events, including incident acute graft-versus-host disease and neutropenia, affected both groups equally, except for taste disturbance (15% maribavir, 6% placebo). Interpretation: Compared with placebo, maribavir prophylaxis did not prevent cytomegalovirus disease when started after engraftment. Cytomegalovirus disease as a primary endpoint might not be sufficient to show improvements in cytomegalovirus prevention in recipients of allogeneic stem-cell transplants in the setting of pre-emptive antiviral treatment. Clinical and virological composite endpoints should be used in future trials. Funding: ViroPharma Incorporated. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
16. Identification of species of viridans group streptococci in clinical blood culture isolates by sequence analysis of the RNase P RNA gene, rnpB.
- Author
-
Westling, Katarina, Julander, Inger, Ljungman, Per, Vondracek, Martin, Wretlind, Bengt, and Jalal, Shah
- Subjects
RNA ,STREPTOCOCCUS ,SEPSIS ,INFECTIVE endocarditis - Abstract
Summary: Objectives: Viridans group streptococci (VGS) cause severe diseases such as infective endocarditis and septicaemia. Genetically, VGS species are very close to each other and it is difficult to identify them to species level with conventional methods. The aims of the present study were to use sequence analysis of the RNase P RNA gene (rnpB) to identify VGS species in clinical blood culture isolates, and to compare the results with the API 20 Strep system that is based on phenotypical characteristics. Methods: Strains from patients with septicaemia or endocarditis were analysed with PCR amplification and sequence analysis of the rnpB gene. Clinical data were registered as well. Results: One hundred and thirty two VGS clinical blood culture isolates from patients with septicaemia (n =95) or infective endocarditis (n =36) were analysed; all but one were identified by rnpB. Streptococcus oralis, Streptococcus sanguinis and Streptococcus gordonii strains were most common in the patients with infective endocarditis. In the isolates from patients with haematological diseases, Streptococcus mitis and S. oralis dominated. In addition in 76 of the isolates it was possible to compare the results from rnpB analysis and the API 20 Strep system. In 39/76 (51%) of the isolates the results were concordant to species level; in 55 isolates there were no results from API 20 Strep. Conclusion: Sequence analysis of the RNase P RNA gene (rnpB) showed that almost all isolates could be identified. This could be of importance for evaluation of the portal of entry in patients with septicaemia or infective endocarditis. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
17. Risk assessment in haematopoietic stem cell transplantation: Viral status.
- Author
-
Ljungman, Per
- Subjects
VIRUS diseases ,COMPLICATIONS from organ transplantation ,STEM cell transplantation ,ORGAN donation ,ORGAN donors - Abstract
Viral infections have been important complications in the transplant procedure from the early days of stem-cell transplantation, causing significant morbidity and mortality. It is important for the management of patients to assess the risk for viral infections that might develop after the stem-cell transplantation. This can be exemplified by cytomegalovirus (CMV) and other herpesviruses, but risk assessment is also important for other viral infections. The aim of this review is to describe current knowledge regarding recipient and donor serological status for viral infections. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
18. The Role of Photochemical Treatment With Amotosalen and UV-A Light in the Prevention of Transfusion-Transmitted Cytomegalovirus Infections.
- Author
-
Roback, John D., Conlan, Maureen, Drew, W. Lawrence, Ljungman, Per, Nichols, W. Garrett, and Preiksaitis, Jutta K.
- Abstract
Primary cytomegalovirus (CMV) infection is usually asymptomatic in immunocompetent patients but can cause serious life-threatening complications in immunocompromised CMV-seronegative patients, including patients receiving a bone marrow or peripheral blood stem cell transplant, recipients of some solid-organ transplants, and low-birth-weight neonates. Current recommendations for preventing transfusion-transmitted CMV (TT-CMV) infection in these patients include exclusive use of CMV-seronegative and/or leukoreduced cellular blood components (red blood cells and platelets) for transfusion. However, breakthrough cases of TT-CMV still occur. Despite improving the safety of blood components, testing remains a reactive approach to blood safety. In contrast, pathogen inactivation technologies offer a proactive approach with the potential to further improve blood safety. To reduce the risks associated with platelet transfusions, a photochemical treatment (PCT) process using a combination of the psoralen amotosalen HCl and long-wavelength UV light has been developed and introduced into clinical practice in Europe. PCT has been shown to result in greater than 5.9-log reductions in infectivity of human CMV in platelet concentrates and to prevent the transfusion transmission of murine CMV in a mouse transfusion model. Thus, PCT pathogen inactivation may play a role in further reducing the incidence of TT-CMV infection in patients who are at risk for serious CMV disease. Because PCT is a technology that targets nucleic acids, it also offers a proactive process for the inactivation of a broad range of viral, bacterial, and protozoan pathogens in addition to CMV. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
19. Varicella zoster virus vaccine in patients with haematological malignancies.
- Author
-
Ljungman, Per
- Subjects
- *
HERPES zoster vaccines , *VIRAL vaccines , *VARICELLA-zoster virus , *VARICELLA-zoster virus diseases , *HERPES zoster , *CHICKENPOX , *BONE marrow transplantation , *HERPESVIRUSES , *CHICKENPOX vaccines , *HEMATOLOGIC malignancies - Published
- 2019
- Full Text
- View/download PDF
20. Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma – Improved Overall Survival in first line Hematopoietic Stem Cell Transplantation.
- Author
-
Gran, Charlotte, Wang, Junfeng, Nahi, Hareth, Koster, linda, Gahrton, Gosta, Wolschke, Christine, Einsele, Hermann, Niittyvoupio, Riitta, Blaise, Didier, Niederwieser, Dietger, Meier, Ellen, Petersen, Eefke, de Wreede, Liesbeth C., Ljungman, Per, Bourhis, Jean Henri, Veelken, Hendrik, Beelen, Dietrich, Stelljes, Matthias, Gerbitz, Armin, and Vincent, Laure
- Published
- 2019
- Full Text
- View/download PDF
21. Outcome of the Rare Myeloma Subtypes- An Analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) Data.
- Author
-
Lawless, Sarah, Morris, Curly, Iacobelli, Simona, Bianchi, Giulia, Bosman, Paul, Blaise, Didier, Reményi, Péter, Russell, Nigel, Mayer, Jiri, Apperley, Jane, Ljungman, Per, Kobbe, Guido, Schaap, N., Isaksson, Cecilia, Lenhoff, Stig, Jędrzejczak, Wieslaw, Chevallier, Patrice, Wilson, Keith, Muñiz, Soledad, and Scheid, Christof
- Published
- 2017
- Full Text
- View/download PDF
22. Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
- Author
-
Phan, Tuan L., Carlin, Kristen, Ljungman, Per, Politikos, Ioannis, Boussiotis, Vicki, Boeckh, Michael, Shaffer, Michele L., and Zerr, Danielle M.
- Subjects
- *
HERPESVIRUSES , *DISEASE risk factors , *GRAFT versus host disease , *STEM cell transplantation , *META-analysis - Abstract
Highlights • HHV-6B is associated with aGVHD after allogeneic HCT. • Patients with HHV-6B reactivation are 2 to 3 times more likely than those without to develop aGVHD. Abstract Graft-versus-host disease (GVHD) is an important cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Many studies have suggested that human herpesvirus-6B (HHV-6B) plays a role in acute GVHD (aGVHD) after HCT. Our objective was to systematically summarize and analyze evidence regarding HHV-6B reactivation and development of aGVHD. PubMed and EMBASE databases were searched using terms for HHV-6, HCT, and aGVHD, yielding 865 unique results. Case reports, reviews, articles focusing on inherited chromosomally integrated HHV-6, poster presentations, and articles not published in English were excluded. The remaining 467 articles were reviewed for the following requirements: a statistical analysis of HHV-6B reactivation and aGVHD was described, HHV-6B reactivation was defined by PCR, and blood (plasma, serum, or peripheral blood mononuclear cells) was used for HHV-6B PCR. Data were abstracted from publications that met these criteria (n = 33). Publications were assigned to 1 of 3 groups: (1) HHV-6B reactivation was analyzed as a time-dependent risk factor for subsequent aGVHD (n = 14), (2) aGVHD was analyzed as a time-dependent risk factor for subsequent HHV-6B reactivation (n = 1), and (3) analysis without temporal specification (n = 18). A statistically significant association (P <.05) between HHV-6B reactivation and aGVHD was observed in 10 of 14 studies (71%) in group 1, 0 of 1 study (0%) in Group 2, and 8 of 18 studies (44.4%) in Group 3. Of the 14 studies that analyzed HHV-6B as a risk factor for subsequent aGVHD, 11 performed a multivariate analysis and reported a hazard ratio, which reached statistical significance in 9 of these studies. Meta-analysis of these 11 studies demonstrated a statistically significant association between HHV-6B and subsequent grades II to IV aGVHD (hazard ratio, 2.65; 95% confidence interval, 1.89 to 3.72; P <.001). HHV-6B reactivation is associated with aGVHD, and when studies have a temporal component to their design, HHV-6B reactivation is associated with subsequent aGVHD. Further research is needed to investigate whether antiviral prophylaxis reduces incidence or severity of aGVHD. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
23. Update to Vaccination Guidelines
- Author
-
Ljungman, Per and Small, Trudy N.
- Published
- 2010
- Full Text
- View/download PDF
24. Solid-organ transplants and the risks of pandemic influenza
- Author
-
Ljungman, Per
- Published
- 2010
- Full Text
- View/download PDF
25. Varicella Zoster Virus Reactivation in Adult Survivors of Hematopoietic Cell Transplantation: How Do We Best Protect Our Patients?.
- Author
-
Lee, Catherine J., Savani, Bipin N., and Ljungman, Per
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *VARICELLA-zoster virus , *VIRUS reactivation , *IMMUNOSUPPRESSION , *GRAFT versus host disease , *HERPES zoster , *VALACYCLOVIR - Abstract
Highlights • Survivors of HCT are at increased risk of VZV reactivation. • Prolonged antiviral prophylaxis with acyclovir or valacyclovir remains the standard preventive measure against VZV reactivation although it remains unclear when it can be stopped. • New vaccines for VZV are in development and under evaluation for prevention of herpes zoster in the HCT population. Abstract Reactivation of varicella zoster virus (VZV) remains a significant public health burden for long-term survivors of hematopoietic cell transplantation. Delayed immune reconstitution after transplantation due to immunosuppression, post-transplant therapies, poor engraftment, and graft-versus-host disease leave a large number of patients at risk for herpes zoster (shingles) and its highly morbid complications. Although prophylaxis with acyclovir or valacyclovir has reduced the incidence of VZV reactivation as long as prophylaxis is continued, the incidence of disease in the late post-transplant period or after stopping prophylaxis is greater in the hematopoietic cell transplantation population than the general public. Therefore, additional interventions beyond long-term use of prophylactic antivirals are required to suppress VZV. Vaccines to elicit VZV-specific immunity represent one method to enhance prevention of VZV reactivation, but care must be taken with live vaccines. Inactivated vaccines have been developed and require well-designed studies to determine their safety and efficacy in this high-risk population. Here, we report the available evidence for established and newly developed vaccines for VZV and discuss our view on their role in protecting our transplant survivors against VZV reactivation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. Viridans group streptococci in blood culture isolates in a Swedish university hospital: antibiotic susceptibility and identification of erythromycin resistance genes
- Author
-
Westling, Katarina, Julander, Inger, Ljungman, Per, Jalal, Shah, Nord, Carl Erik, and Wretlind, Bengt
- Subjects
- *
ANTIBACTERIAL agents , *PENICILLIN , *BETA lactam antibiotics , *ANTIBIOTICS - Abstract
Abstract: One hundred and twenty-nine isolates of viridans group streptococci in blood cultures from patients with septicaemia or endocarditis isolated between 1998 and 2003 were tested for antibiotic susceptibility to penicillin, ciprofloxacin, clindamycin, dalbavancin, daptomycin, erythromycin, linezolid, tigecycline, trimethoprim/sulphamethoxazole and vancomycin. Reduced susceptibility to penicillin (minimum inhibitory concentration (MIC) ≥0.25μg/mL) was found in 18% of the isolates, and 4% of the strains were resistant to penicillin (MIC≥4.0μg/mL). Nineteen percent of the isolates had reduced susceptibility to erythromycin (MIC≥0.5μg/mL), among which ermB and mefA were found in 40% and 80%, respectively. Strains sequenced as Streptococcus mitis by rnpB had a high degree of non-susceptibility to erythromycin (32%) and penicillin (21%). The level of penicillin resistance in this Swedish study was lower compared with studies from other countries where the antibiotic pressure might be higher than in Sweden. Susceptibility to newer antibiotics was high; all strains were susceptible to dalbavancin, daptomycin, linezolid and vancomycin. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
27. A real-time TaqMan PCR for routine quantitation of cytomegalovirus DNA in crude leukocyte lysates from stem cell transplant patients
- Author
-
Yun, Zhibing, Lewensohn-Fuchs, Ilona, Ljungman, Per, Ringholm, Lotta, Jonsson, Jerker, and Albert, Jan
- Subjects
- *
STEM cells , *POLYMERASE chain reaction - Abstract
A real-time TaqMan PCR based on the cytomegalovirus (CMV) polymerase (pol) gene was developed for quantitation of CMV DNA in crude peripheral blood leukocyte (PBL) lysate from stem cell transplantation (SCT) patients. The dynamic range of the assay was between 10 and 4×106 copies. Both intra- and inter-assay variability were well within ±0.25 log10 S.D. Thus, a pooled PBL sample that was used as positive control in 57 consecutive TaqMan PCR runs over 7 months showed a stable CMV quantity (4.12±0.13, log10 mean±S.D.). The sensitivity of the pol TaqMan PCR was validated by parallel analysis of 177 PBL samples with a nested PCR. The use of crude PBL lysate as PCR input did not cause PCR inhibition. We demonstrated further the clinical utility of the newly developed TaqMan PCR by monitoring changes in CMV levels in eight patients receiving antiviral therapy. This TaqMan PCR was highly sensitive, reproducible, and stable and has served a useful tool for monitoring CMV DNA levels in large number of clinical samples in a routine diagnostic setting for over 1 year. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
28. Vaccination against tick-borne encephalitis (TBE) after autologous and allogeneic stem cell transplantation.
- Author
-
Einarsdottir, Sigrun, Nicklasson, Malin, Veje, Malin, Bergström, Tomas, Studahl, Marie, Lisak, Mikael, Olsson, Mikael, Johansson, Berit, Andreasson, Björn, Piauger, Bénédicte, Roth, Anette, Friman, Vanda, Ljungman, Per, and Brune, Mats
- Subjects
- *
TICK-borne encephalitis , *STEM cell transplantation , *VACCINATION , *IMMUNOCOMPROMISED patients - Abstract
• Tick-borne encephalitis (TBE) can result in severe disease in immunocompromised patients. • Four vaccine doses induced seropositivity in a majority (77%) of patients. • We found no safety issues using FSME-immun® after stem cell transplant. • Graft-versus host disease (GVHD) was associated with lower antibody levels. • It seems important to prime patients with four vaccine doses. Our aim was to assess response and side effects of 4 doses of TBE vaccine to patients (pts) after allo- and autologous stem cell transplantation (SCT). PATIENTS: Included were 104 pts with leukaemia, myeloma and lymphoma, median age 61 yrs. METHODS: Vaccine (FSME-Immun®) was given at 9, 10, 12, and 21 months post-transplant. Serum samples were obtained before and after vaccinations. Healthy controls (n = 27) received 3 vaccinations. Assessments of TBE specific IgG antibodies were performed by Enzygnost anti-TBE ELISA test (Siemens, Sweden). Antibody levels (>12 U/mL; "seropositivity") were seen in 77% and 80% of pts after allo- and autoSCT; IgG levels; 89 vs 94 U/mL. Ongoing chronic GvHD and immunosuppression (n = 29) was associated with sero-negativity in the last sample (p = 0.007). All controls (n = 27) developed protective antibody levels. TBE vaccination was safe, and 4 doses starting 9 months post-SCT, induced seropositivity in a vast majority of pts. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee
- Author
-
Algwaiz, Ghada, Aljurf, Mahmoud, Koh, Mickey, Horowitz, Mary M., Ljungman, Per, Weisdorf, Daniel, Saber, Wael, Kodera, Yoshihisa, Szer, Jeff, Jawdat, Dunia, Wood, William A., Brazauskas, Ruta, Lehmann, Leslie, Pasquini, Marcelo C., Seber, Adriana, Lu, Pei Hua, Atsuta, Yoshiko, Riches, Marcie, Perales, Miguel-Angel, and Worel, Nina
- Subjects
- *
COVID-19 pandemic , *CELL transplantation , *MEDICAL care , *BONE marrow , *WORLD health , *PANDEMICS - Abstract
The current COVID-19 pandemic, caused by SARS-CoV-2, has impacted many facets of hematopoietic cell transplantation (HCT) in both developed and developing countries. Realizing the challenges as a result of this pandemic affecting the daily practice of the HCT centers and the recognition of the variability in practice worldwide, the Worldwide Network for Blood and Marrow Transplantation (WBMT) and the Center for International Blood and Marrow Transplant Research's (CIBMTR) Health Services and International Studies Committee have jointly produced an expert opinion statement as a general guide to deal with certain aspects of HCT, including diagnostics for SARS-CoV-2 in HCT recipient, pre- and post-HCT management, donor issues, medical tourism, and facilities management. During these crucial times, which may last for months or years, the HCT community must reorganize to proceed with transplantation activity in those patients who urgently require it, albeit with extreme caution. This shared knowledge may be of value to the HCT community in the absence of high-quality evidence-based medicine. © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
30. High Graft-versus-Host Disease-Free, Relapse/Rejection-Free Survival and Similar Outcome of Related and Unrelated Allogeneic Stem Cell Transplantation for Aplastic Anemia: A Nationwide Swedish Cohort Study.
- Author
-
Vaht, Krista, Göransson, Magnus, Carlson, Kristina, Isaksson, Cecilia, Lenhoff, Stig, Sandstedt, Anna, Uggla, Bertil, Winiarski, Jacek, Ljungman, Per, Andersson, Per-Ola, and Brune, Mats
- Subjects
- *
STEM cell transplantation , *APLASTIC anemia , *STEM cell donors , *COHORT analysis - Abstract
• We studied all patients with aplastic anemia (AA) in Sweden diagnosed between 2000 and 2011 who underwent allogeneic stem cell transplantation (allo-SCT). • The graft-versus-host disease-free, relapse/rejection-free survival (GRFS) was high. • Allo-SCT for patients with AA aged ≥40 years was more problematic, with higher transplant-related mortality and lower overall survival as well as inferior GRFS, and clinical trials addressing this issue are warranted. Allogeneic stem cell transplantation (SCT) as primary treatment for aplastic anemia (AA) is being increasingly used. Yet, age, stem cell source, and donor type are important outcome factors. We have recently performed a nationwide cohort study of all patients with AA in Sweden diagnosed from 2000 to 2011 and now present outcome data on SCT patients. In total, 68 patients underwent SCT, and 63% of them had failed immunosuppressive therapy. We found that, with a median follow-up of 109 months (range, 35 to 192 months), 5-year overall survival (OS) for all patients was 86.8%, whereas graft-versus-host disease-free, relapse/rejection-free survival (GRFS) at 5 years was 69.1%. There was no survival impact regarding the donor type or stem cell source. Patients aged ≥40 years had a higher transplant-related mortality (29.4% versus 7.8%; P =.023), which translated into a lower 5-year OS: 70.6% versus 92.2% (P =.022) and a trend of lower GRFS (52.9% versus 74.5%; P =.069). In conclusion, we found in this real-world setting that both OS and GRFS were high, but SCT for patients with AA aged ≥40 years is problematic, and clinical trials addressing this issue are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
31. Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7).
- Author
-
Mikulska, Malgorzata, Cesaro, Simone, de Lavallade, Hugues, Di Blasi, Roberta, Einarsdottir, Sigrun, Gallo, Giuseppe, Rieger, Christina, Engelhard, Dan, Lehrnbecher, Thomas, Ljungman, Per, Cordonnier, Catherine, and European Conference on Infections in Leukaemia group
- Subjects
- *
VACCINATION , *THERAPEUTICS , *IMMUNOCOMPROMISED patients , *TRANSPLANTATION of organs, tissues, etc. , *IMMUNODEFICIENCY - Abstract
Patients with haematological malignancies are at high risk of infection because of various mechanisms of humoral and cell-mediated immune deficiencies, which mainly depend on underlying disease and specific therapies. Some of these infections are vaccine preventable. However, these malignancies are different from each other, and the treatment approaches are diverse and rapidly evolving, so it is difficult to have a common programme for vaccination in a haematology ward. Additionally, because of insufficient training about the topic, vaccination is an area often neglected by haematologists, and influenced by cultural differences, even among health-care workers, in compliance to vaccines. Several issues are encountered when addressing vaccination in haematology: the small size of the cohorts that makes it difficult to show the clinical benefits of vaccination, the subsequent need to rely on biological parameters, their clinical pertinence not being established in immunocompromised patients, scarcity of clarity on the optimal timing of vaccination in complex treatment schedules, and the scarcity of data on long-term protection in patients receiving treatments. Moreover, the risk of vaccine-induced disease with live-attenuated vaccines strongly limits their use. Here we summarise guidelines for patients without transplantations, and address the issue by the haematological group-myeloid and lymphoid-of diseases, with a special consideration for children with acute leukaemia. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
32. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7).
- Author
-
Cordonnier, Catherine, Einarsdottir, Sigrun, Cesaro, Simone, Di Blasi, Roberta, Mikulska, Malgorzata, Rieger, Christina, de Lavallade, Hugues, Gallo, Giuseppe, Lehrnbecher, Thomas, Engelhard, Dan, Ljungman, Per, and European Conference on Infections in Leukaemia group
- Subjects
- *
STEM cell transplantation , *IMMUNIZATION of children , *VACCINATION , *GRAFT versus host disease , *STREPTOCOCCUS pneumoniae , *VACCINE effectiveness , *PREVENTION of communicable diseases , *HEMATOPOIETIC stem cell transplantation , *IMMUNIZATION , *MEDICAL protocols , *VACCINES , *IMMUNOCOMPROMISED patients , *DISEASE complications - Abstract
Infection is a main concern after haemopoietic stem cell transplantation (HSCT) and a major cause of transplant-related mortality. Some of these infections are preventable by vaccination. Most HSCT recipients lose their immunity to various pathogens as soon as the first months after transplant, irrespective of the pre-transplant donor or recipient vaccinations. Vaccination with inactivated vaccines is safe after transplantation and is an effective way to reinstate protection from various pathogens (eg, influenza virus and Streptococcus pneumoniae), especially for pathogens whose risk of infection is increased by the transplant procedure. The response to vaccines in patients with transplants is usually lower than that in healthy individuals of the same age during the first months or years after transplant, but it improves over time to become close to normal 2-3 years after the procedure. However, because immunogenic vaccines have been found to induce a response in a substantial proportion of the patients as early as 3 months after transplant, we recommend to start crucial vaccinations with inactivated vaccines from 3 months after transplant, irrespectively of whether the patient has or has not developed graft-versus-host disease (GvHD) or received immunosuppressants. Patients with GvHD have higher risk of infection and are likely to benefit from vaccination. Another challenge is to provide HSCT recipients the same level of vaccine protection as healthy individuals of the same age in a given country. The use of live attenuated vaccines should be limited to specific situations because of the risk of vaccine-induced disease. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
33. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.
- Author
-
Raj, Kavita, Eikema, Diderik-Jan, McLornan, Donal P, Olavarria, Eduardo, Blok, Henric-Jan, Bregante, Stefania, Ciceri, Fabio, Passweg, Jakob, Ljungman, Per, Schaap, Nicolaas, Carlson, Kristina, Zuckerman, Tsila, de Wreede, Liesbeth C., Volin, Liisa, Koc, Yener, Diez-Martin, Jose Luis, Brossart, Peter, Wolf, Dominik, Blaise, Didier, and Bartolomeo, Paolo Di
- Subjects
- *
STEM cell transplantation , *PROGRESSION-free survival , *MYELOFIBROSIS , *BONE marrow , *ALEMTUZUMAB , *BLOOD , *TRANSPLANTATION of organs, tissues, etc. - Abstract
Highlights • We performed a retrospective review of 56 myelofibrosis patients transplanted from mismatched family donors. • Neutrophil engraftment at a median of 20days was observed in 82%. • Low rates of acute GVHD grades II to IV were observed in 28% (16% to 40%) and grades III to IV in 9% (2% to 16%). • Chronic GVHD at 1 year was found in 45% (32% to 58%). • Overall survival at 2years was 56% (41% to 70%). Abstract This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow Transplantation database. The median age was 57years (range, 38 to 72); 75% had primary MF and 25% had secondary MF. JAK2 V617F was mutated in 61%. Donors were HLA mismatched at 2 or more loci. Stem cells were sourced from bone marrow in 66% and peripheral blood in 34%. The median CD34+ cell dose was 4.8 × 106/kg (range, 1.7 to 22.9; n = 43). Conditioning was predominantly myeloablative in 70% and reduced intensity in the remainder. Regimens were heterogeneous with thiotepa, busulfan, fludarabine, and post-transplant cyclophosphamide used in 59%. The incidence of neutrophil engraftment by 28days was 82% (range, 70% to 93%), at a median of 21days (range, 19 to 23). At 2years the cumulative incidence of primary graft failure was 9% (95% CI 1% to 16%) and secondary graft failure was 13% (95% CI 4% to 22%). The cumulative incidence of acute graft-versus-host disease (GVHD) grades II to IV and III to IV was 28% (95% CI 16% to 40%) and 9% (95% CI 2% to 17%) at 100days. The cumulative incidence of chronic GVHD at 1 year was 45% (95% CI 32% to 58%), but the cumulative incidence of death without chronic GVHD by 1 year was 20% (95% CI 10% to 31%). With a median follow-up of 32 months, the 1- and 2-year overall survival was 61% (95% CI 48% to 74%) and 56% (95% CI 41% to 70%), respectively. The 1- and 2- year progression-free survival was 58% (95% CI 45% to 71%) and 43% (95% CI 28% to 58%), respectively, with a 2-year cumulative incidence of relapse of 19% (95% CI 7% to 31%). The 2-year nonrelapse mortality was 38% (95% CI 24% to 51%). This retrospective study of MF allo-SCT using family mismatched donors demonstrated feasibility of the approach, timely neutrophil engraftment in over 80% of cases, and acceptable overall and progression-free survival rates with relapse rates not dissimilar to the unrelated donor setting. However, strategies to minimize the risk of graft failure and the relatively high nonrelapse mortality need to be used, ideally in a multicenter prospective fashion. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
34. Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT.
- Author
-
Giebel, Sebastian, Labopin, Myriam, Czerw, Tomasz, Socié, Gérard, Blaise, Didier, Ghavamzadeh, Ardeshir, Passweg, Jacob, Ljungman, Per, Poiré, Xavier, Chevallier, Patrice, Reményi, Péter, Rambaldi, Alessandro, Anafasyev, Boris, Fegueux, Nathalie, Rovira, Montserrat, Itälä-Remes, Maija, Bornhäuser, Martin, Mohty, Mohamad, and Nagler, Arnon
- Subjects
- *
GRAFT versus host disease prevention , *ANTILYMPHOCYTIC serum , *CHROMOSOME abnormalities , *GRAFT versus host disease , *CHRONIC diseases , *HEMATOPOIETIC stem cell transplantation , *LYMPHOBLASTIC leukemia , *MULTIVARIATE analysis , *POSTOPERATIVE period , *PROBABILITY theory , *SURVIVAL , *DISEASE relapse , *DISEASE incidence , *DISEASE remission , *RETROSPECTIVE studies , *ODDS ratio , *DISEASE risk factors , *PROGNOSIS , *THERAPEUTICS ,MORTALITY risk factors - Abstract
Abstract Background Anti-thymocyte globulin (ATG) is widely used to prevent graft-versus-host disease (GVHD) after allogeneic peripheral blood stem cell transplantation (alloPBSCT). The goal of this study was to retrospectively assess the effect of ATG on outcomes in the setting of Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL). Methods In the analysis, 1170 adult patients undergoing alloPBSCT from human leucocyte antigen–matched sibling or unrelated donors in the first complete remission between 2007 and 2016 were included. ATG was used in 429/575 (75%) and 121/595 (20%) patients transplanted from unrelated or sibling donors, respectively. Results The incidence of chronic GVHD was 35% for patients treated with ATG compared with 52% in those not receiving ATG (p < 0.001), while the rate of extensive chronic GVHD was 16% and 36%, respectively (p < 0.001). The probability of survival free from GVHD and relapse (GRFS) was 42% and 32%, respectively (p = 0.002). In a multivariate model, the use of ATG was associated with reduced risk of overall chronic GVHD (hazard ratio [HR] = 0.52, p < 0.001) and extensive chronic GVHD (HR = 0.46, p < 0.001). It was also associated with better GRFS (HR = 0.77, p = 0.007), despite increased risk of relapse (HR = 1.41, p = 0.02). No significant effect was found with regard to the risk of non-relapse mortality and overall mortality. Conclusions The use of ATG for patients with Ph+ ALL undergoing alloPBSCT is associated with reduced risk of chronic GVHD without impact on survival and therefore, could be considered. However, increased risk of relapse suggests the need for strict monitoring of minimal residual diseases and appropriate interventions after transplantation. Highlights • Decreased risk of chronic graft-versus-host disease for patients treated with anti-thymocyte globulin (ATG). • Increased risk of relapse associated with the use of ATG. • No impact on survival associated with the use of ATG. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
35. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.
- Author
-
Sahebi, Firoozeh, Iacobelli, Simona, Sbianchi, Giulia, Koster, Linda, Blaise, Didier, Reményi, Péter, Russell, Nigel H., Ljungman, Per, Kobbe, Guido, Apperley, Jane, Trneny, Marek, Krejci, Marta, Wiktor-Jedrzejczak, Wieslaw, Sanchez, James F., Schaap, Nicolaas, Isaksson, Cecilia, Lenhoff, Stig, Browne, Paul, Scheid, Christof, and Wilson, Keith M.O.
- Subjects
- *
MULTIPLE myeloma , *AUTOTRANSPLANTATION , *DISEASE incidence , *TARGETED drug delivery , *HEMATOPOIETIC stem cell transplantation - Abstract
The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPMs). We examined the SPM rate in MM patients who were enrolled in the prospective observational CALM (Collaboration to Collect Autologous Transplant outcome in Lymphoma and Myeloma) study. Between 2008 and 2012, 3204 patients with MM underwent a first autologous hematopoietic stem cell transplantation. Plerixafor was used as a mobilizing agent for patients with poor (or potentially poor) stem cell mobilization as defined by the respective centers. A total of 135 patients developed SPMs, with a cumulative incidence of 5.3% (95% confidence interval, 4.4 to 6.3) at 72 months. Ninety-four patients developed solid tumors, 30 developed hematologic malignancies, and 11 developed an SPM of an unknown type. The cumulative incidence of known hematologic and solid malignancies were 1.4% and 3.6%, respectively, at 72 months. In a univariate analysis, use of radiotherapy, type of induction regimen, hematopoietic stem cell dose, poor mobilizer status, plerixafor use, and sex did not influence the cumulative incidence of SPMs. Only age over 65 years was statistically associated with an increased incidence. Overall, the incidence of SPMs was comparable to earlier estimations of SPMs in MM. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
36. Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion.
- Author
-
Garderet, Laurent, Ziagkos, Dimitris, van Biezen, Anja, Iacobelli, Simona, Finke, Jürgen, Maertens, Johan, Volin, Liisa, Ljungman, Per, Chevallier, Patrice, Passweg, Jakob, Schaap, Nicolaas, Beelen, Dietrich, Nagler, Arnon, Blaise, Didier, Poiré, Xavier, Yakoub-Agha, Ibrahim, Lenhoff, Stig, Craddock, Charles, Schots, Rik, and Rambaldi, Alessandro
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *MYELODYSPLASTIC syndromes treatment , *HOMOGRAFTS , *DELETION mutation , *DISEASE incidence , *SURVIVAL analysis (Biometry) - Abstract
The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
37. Measuring Immune Response to Commonly Used Vaccinations in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation.
- Author
-
Kennedy, Lucy Boyce, Li, Zhuoyan, Savani, Bipin N., and Ljungman, Per
- Subjects
- *
IMMUNE response , *HEMATOPOIETIC stem cell transplantation , *VACCINATION , *IMMUNOGLOBULINS , *GRAFT versus host disease - Abstract
Recipients of hematopoietic cell transplantation (HCT) are at risk for potentially preventable infectious complications because of defects in humoral and cell-mediated immunity. Studies of vaccine immunogenicity in HCT recipients have shown that antibody response rates depend on age, type of vaccine, and presence or absence of graft-versus-host disease. However, few large-scale studies have assessed the immune response to vaccination in HCT recipients. Additionally, HCT recipients have much higher rates of potentially preventable infections compared with the general population even after vaccination. This review evaluates the available studies and our view on the measurement of specific antibody titers, definition of an immune response, and durability of response in HCT recipients in both inactivated and live attenuated vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
38. Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based Decisions.
- Author
-
Törlén, Johan, Remberger, Mats, Le Blanc, Katarina, Ljungman, Per, and Mattsson, Jonas
- Subjects
- *
STEM cell transplantation , *RETROSPECTIVE studies , *HEMATOLOGY , *HEALTH outcome assessment , *MORTALITY - Abstract
Outcome after allogeneic hematopoietic stem cell transplantation is influenced by patient comorbidity, disease type, and status before treatment. We performed a retrospective study involving 521 consecutive adult hematopoietic stem cell transplantation patients who underwent transplantation for hematological malignancy at our center from 2000 to 2012 to compare the predictive value of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) and the disease risk index (DRI) for overall survival and transplantation-related mortality. Patients in the highest HCT-CI risk group (HCT-CI score ≥3) had a lower 5-year overall survival rate (50%) than the low-risk group (63%; P < .01). Subset analysis of donor origin showed greater 5-year overall survival in siblings than in matched unrelated donors, regardless of HCT-CI score (eg, 67% 5-year overall survival in siblings despite an HCT-CI score of >6 [n = 9]). Five-year overall survival in the highest DRI risk group was significantly poorer (44%) than in the low-risk group (63%; P < .01). Both indices failed to predict differences in transplantation-related mortality (HCT-CI, P = .54; DRI, P = .17). We conclude that HCT-CI and DRI were predictive of overall survival in our patient population. Even so, our data show that different patient groups may have different outcomes despite sharing the same index risk group and that indices should, therefore, be evaluated according to local data before clinical implementation at the single-center level. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
39. Risk Factors for Invasive Mold Infections and Implications for Choice of Prophylaxis after Allogeneic Stem Cell Transplantation.
- Author
-
Blennow, Ola, Remberger, Mats, Törlén, Johan, Szakos, Attila, Ljungman, Per, and Mattsson, Jonas
- Subjects
- *
MYCOSES , *PREVENTIVE medicine , *STEM cell transplantation , *COMPLICATIONS from organ transplantation , *DEATH rate , *GRAFT versus host disease , *DISEASE risk factors - Abstract
Invasive mold infections (IMIs) are major complications after allogeneic hematopoietic stem cell transplantation (HSCT) with high mortality. We retrospectively investigated incidence and risk factors for IMI after 797 HSCTs in a center with high autopsy frequency, trying to identify patient groups that would potentially benefit from mold-active prophylaxis. The cumulative 1-year incidence of IMI was 2.1% in patients aged 21 to 40, 7.1% in patients aged 41 to 60, and 16.4% in patients > 60 years of age ( P < .01 for patients aged 21 to 40 versus 41 to 60, P < .001 for patients aged 21 to 40 versus patients > 60). Risk factors for a new IMI in multivariate analysis were older age, grades II to IV acute graft-versus-host disease (GVHD) (risk hazard, 4.1; 95% CI, 1.9 to 8.8; P < .001), treatment with mesenchymal stromal cells (risk hazard, 4.0; 95% CI, 2.1 to 7.8; P < .001), transplantation with female donor to male recipient (risk hazard, 2.2; 95% CI, 1.1 to 4.3; P = .02), and hematopoietic stem cell transplantation–specific comorbidity index over 5 (risk hazard, 2.8; 95% CI, 1.1 to 6.8; P = .03). In patients with grade II acute GVHD, no IMI was seen after onset of acute GVHD in 109 HSCTs performed in patients < 40 years of age, as compared with 14 IMIs in 97 HSCTs (14%) performed in patients > 40 years of age ( P < .001). To conclude, older age is an important risk factor for developing IMIs, and patients < 40 years of age with grade II acute GVHD do not appear to need mold-active prophylaxis unless receiving prolonged treatment with corticosteroids. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
40. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research
- Author
-
Potter, Victoria T., Iacobelli, Simona, van Biezen, Anja, Maertens, Johann, Bourhis, Jean-Henri, Passweg, Jakob R., Yakhoub-Agha, Ibrahim, Tabrizi, Reza, Bay, Jacques-Olivier, Chevallier, Patrice, Chalandon, Yves, Huynh, Anne, Cahn, Jean Yves, Ljungman, Per, Craddock, Charles, Lenhoff, Stig, Russell, N.H., Fegueux, Nathalie, Socié, Gerard, and Benedetto, Bruno
- Subjects
- *
CANCER chemotherapy , *STEM cell transplantation , *HEALTH outcome assessment , *MORTALITY , *MYELODYSPLASTIC syndromes , *PATIENTS - Abstract
The European Society for Blood and Marrow Transplant Research data set was used to retrospectively analyze the outcomes of hypomethylating therapy (HMA) compared with those of conventional chemotherapy (CC) before hematopoietic stem cell transplantation (HSCT) in 209 patients with advanced myelodysplastic syndromes. Median follow-up was 22.1 months and the median age of the group was 57.6 years with 37% of the population older than > 60 years. The majority of patients (59%) received reduced-intensity conditioning and 34% and 27% had intermediate-2 and high international prognostic scoring system (IPSS) scores. At time of HSCT, 32% of patients did not achieve complete remission (CR) and 13% had primary refractory disease. On univariate analysis, outcomes at 3 years were not significantly different between HMA and CC for overall survival (OS), relapse-free survival (RFS), cumulative incidence of relapse (CIR), and nonrelapse mortality (NRM): OS (42% versus 35%), RFS (29% versus 31%), CIR (45% versus 40%), and NRM (26% versus 28%). Comparing characteristics of the groups, there were more patients < 55 years old, more patients in CR (68% versus 32%), and fewer patients with primary refractory disease in the CC group than in the HMA group (10% versus 19%, P < .001). Patients with primary refractory disease had worse outcomes than those in CR with regard to OS (hazard ratio [HR], 2.42; 95% confidence interval [CI], 1.41 to 4.13; P = .001), RFS (HR, 2.27; 95% CI, 1.37 to 3.76; P = .001), and NRM (HR, 2.49; 95% CI, 1.18 to 5.26; P = .016). In addition, an adverse effect of IPSS-R cytogenetic risk group was evident for RFS. In summary, outcomes after HSCT are similar for patients receiving HMA compared with those receiving CC, despite the higher proportion of patients with primary refractory disease in the HMA group. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
41. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5).
- Author
-
Mallet, Vincent, van Bömmel, Florian, Doerig, Christopher, Pischke, Sven, Hermine, Olivier, Locasciulli, Anna, Cordonnier, Catherine, Berg, Thomas, Moradpour, Darius, Wedemeyer, Heiner, Ljungman, Per, and ECIL-5
- Subjects
- *
VIRAL hepatitis , *STEM cell transplantation , *CHRONIC myeloid leukemia , *CANCER chemotherapy , *PATIENTS , *THERAPEUTICS - Abstract
Viral hepatitis affects millions of people worldwide, and host immunity is the key determinant of patient outcome. Viral hepatitis can be life threatening in patients with haematological malignancy, including haemopoietic stem cell transplant recipients, because of the virus itself, or through a need to decrease the dose of chemotherapy. A past or currently infected haemopoietic stem cell donor could also transmit viral hepatitis. The burden of viral hepatitis in patients with haematological malignancies and the weak evidence on which previous guidelines are based has prompted the European Conference on Infection in Leukaemia (ECIL-5) to convene a group of experts in the fields of viral hepatitis and of haematological malignancy to specifically address previously unconsidered issues and grade the available quality of evidence according to the Infectious Diseases Society of America grading system. The group recommends that all patients should be screened for hepatotropic viruses before haematological treatment and that patients or haemopoietic stem cell donors with markers of past or current viral hepatitis should be assessed by an expert. Screening, vaccination, and treatment rules are reported in this Review. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
42. Varicella-Zoster Reactivation after Allogeneic Stem Cell Transplantation without Routine Prophylaxis—The Incidence Remains High.
- Author
-
Blennow, Ola, Fjaertoft, Gustav, Winiarski, Jacek, Ljungman, Per, Mattsson, Jonas, and Remberger, Mats
- Subjects
- *
VIRAL disease prevention , *STEM cell transplantation , *DENTAL prophylaxis , *VARICELLA-zoster virus diseases , *ACYCLOVIR , *COHORT analysis , *MESENCHYMAL stem cells - Abstract
One-year prophylaxis with acyclovir has been shown to effectively prevent varicella-zoster virus (VZV) reactivation after allogeneic hematopoietic stem cell transplantation (HSCT) in a cohort that underwent transplantation in the beginning of the 2000s. Transplantation procedures have since changed considerably and reduced-intensity conditioning (RIC) is nowadays common. We investigated VZV reactivation without routine prophylaxis in a cohort of HSCT patients, 50% of whom had received RIC. The cumulative 2-year incidence of VZV reactivation was 20.7%. Risk factors in a multivariate analysis were treatment with mesenchymal stromal cells (relative hazard [RH], 1.65; confidence interval [CI], 1.07 to 2.54; P = .02), total body irradiation ≥6 Gy (RH, 1.55; CI, 1.14 to 2.13; P = .006), engraftment later than day 16 (RH, 1.46; CI, 1.07 to 2.00; P = .02), and age 0 to 19 years (RH, 1.68; CI, 1.21 to 2.35; P = .002). There was no difference in VZV reactivation between patients receiving myeloablative conditioning or RIC. VZV-related complications occurred in 29% of the patients with reactivation; most common were disseminated disease and postherpetic neuralgia. No single low-risk group for VZV reactivation could be identified. We conclude that VZV reactivation remains common after HSCT and carries a high complication rate, warranting prophylaxis. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
43. Analysis of Donor and Recipient ABO Incompatibility and Antibody-Associated Complications after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning.
- Author
-
Watz, Emma, Remberger, Mats, Ringden, Olle, Lundahl, Joachim, Ljungman, Per, Mattsson, Jonas, Wikman, Agneta, and Uhlin, Michael
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *COMPLICATIONS from organ transplantation , *AUTOIMMUNE hemolytic anemia , *HEALTH outcome assessment , *ABO blood group system , *MULTIVARIATE analysis , *ANTI-antibodies - Abstract
Abstract: Allogeneic hematopoietic stem cell transplantation (HSCT) can be performed across the ABO blood group barrier. The impact of ABO incompatibility on clinical outcome is controversial. A retrospective analysis of 310 patients who underwent HSCT with reduced-intensity conditioning between 1998 and 2011 was performed to investigate the frequency and clinical implications of anti-RBC antibodies in passenger lymphocyte syndrome (PLS) after minor ABO mismatch (mm), persistent or recurring recipient type ABO antibodies (PRABO) after major ABO mm HSCT, and autoimmune hemolytic anemia (AIHA). Transplantation characteristics and clinical outcome were analyzed by univariate and multivariate analysis for groups with or without anti-RBC antibodies. ABO blood group incompatibility did not affect clinical outcome despite an increased requirement of blood transfusion. Twelve patients with AIHA, 6 patients with PLS, and 12 patients with PRABO post-HSCT were identified. AIHA did not affect overall survival (OS) or transplant-related mortality (TRM), but patients with AIHA had a lower incidence of grades II to IV acute graft-versus-host disease (P = .05). OS in the PLS group was 0% compared with 61% in the whole group receiving minor ABO mm transplants (P < .001). Comparing PRABO patients with those receiving a major ABO mm HSCT, the OS was 17% versus 73% (P = .002) and TRM was 50% versus 21% (P = .03). At our center, PLS after minor ABO mm and PRABO antibodies after major ABO mm HSCT are significant risk factors for decreased OS and TRM. Our results suggest that occurrence of unexpected ABO antibodies after HSCT warrant a wider investigation individual to find the underlying cause. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
44. Reduced IL-7 Responsiveness Defined by Signal Transducer and Activator of Transcription 5 Phosphorylation in T Cells May Be a Marker for Increased Risk of Developing Cytomegalovirus Disease in Patients after Hematopoietic Stem Cell Transplantation.
- Author
-
Pérez-Bercoff, Lena, Vudattu, Nalini K., Byrareddy, Siddappa N., Mattsson, Jonas, Maeurer, Markus, and Ljungman, Per
- Subjects
- *
INTERLEUKIN-7 , *CELLULAR signal transduction , *GENETIC transcription , *PHOSPHORYLATION , *T cells , *CYTOMEGALOVIRUS diseases , *HEMATOPOIETIC stem cell transplantation - Abstract
Abstract: Cytomegalovirus (CMV) reactivation may lead to CMV disease associated with high morbidity and mortality in patients after hematopoietic stem cell transplantation (HSCT); the identification of clinically relevant markers may aid in the identification of patients at increased risk for developing CMV-associated complications. We evaluated the phosphorylation of signal transducer and activator of transcription 5 (STAT5) in CD4+ T cells, CD8+ T cells, and TCRγδ T cells in response to stimulation with IL-7 or IL-2 after HSCT by analyzing blood samples taken monthly 1 to 6 months after HSCT. Patients were monitored weekly with a quantitative PCR from the time of engraftment for CMV viral load in whole blood until at least day 100 after HSCT. We identified a correlation between clinical outcome regarding CMV replication and the ability to respond to IL-7 and IL-2 defined by STAT5 phosphorylation (pSTAT5). Patients with recurrent or prolonged CMV replications had significantly lower pSTAT5 upon stimulation of T cells with either IL-7 or IL-2 at time points 1 through 3 than those without CMV replication (P < .05). This was also found after stimulation of CD8+ T cells at time point 2 (P < .05). We conclude that reduced responses to IL-7, reflected by pSTAT5, may represent a clinically relevant functional biomarker for individuals at increased risk for CMV reactivation; our data may also aid in designing better strategies to improve anti-CMV immune responses without increasing the risk of developing graft-versus-host disease. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
45. Priorities for CMV vaccine development.
- Author
-
Krause, Philip R., Bialek, Stephanie R., Boppana, Suresh B., Griffiths, Paul D., Laughlin, Catherine A., Ljungman, Per, Mocarski, Edward S., Pass, Robert F., Read, Jennifer S., Schleiss, Mark R., and Plotkin, Stanley A.
- Subjects
- *
CYTOMEGALOVIRUS diseases , *CONGENITAL disorders , *IMMUNOCOMPROMISED patients , *VIRAL vaccines , *CYTOMEGALOVIRUS disease prevention , *PATIENTS - Abstract
Highlights: [•] A January 2012 meeting addressed priorities for development of vaccines to prevent disease caused by cytomegalovirus (CMV). [•] CMV causes serious disease, including congenital CMV and life-threatening infections in immunocompromised patients. [•] Discussions identified appropriate target populations for vaccine use and appropriate endpoints for vaccine studies. [•] Participants at the meeting also made specific suggestions for further research that could facilitate CMV vaccine development. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
46. Viral Infections in Immunocompromised Patients
- Author
-
Englund, Janet, Feuchtinger, Tobias, and Ljungman, Per
- Published
- 2011
- Full Text
- View/download PDF
47. Long-Term Complications, Immunologic Effects, and Role of Passage for Outcome in Mesenchymal Stromal Cell Therapy
- Author
-
von Bahr, Lena, Sundberg, Berit, Lönnies, Lena, Sander, Birgitta, Karbach, Holger, Hägglund, Hans, Ljungman, Per, Gustafsson, Britt, Karlsson, Helen, Le Blanc, Katarina, and Ringdén, Olle
- Subjects
- *
CELLULAR therapy , *STROMAL cells , *GRAFT versus host disease , *INTERLEUKINS , *CANCER relapse , *CYTOMEGALOVIRUS diseases , *THERAPEUTIC complications - Abstract
Thirty-one patients treated with mesenchymal stromal cells (MSCs) for acute graft-versus-host disease (aGVHD) or hemorrhagic cystitis between 2002 and 2007 were followed to investigate predictors of outcome, immunologic effects in vivo, and long-term survival. There was no correlation between in vitro suppression by MSCs in mixed lymphocyte cultures and outcome. Soluble IL-2 receptors were measured in blood before and after MSC infusion and declined significantly during the first week after MSC infusion (P = .03). Levels of interleukin-6 and HLA-G were unaffected. Infectious complications occurred several years after recovery from aGVHD. Cytomegalovirus viral load was high, and cytomegalovirus disease was common. Among patients recovering from aGVHD, 54% died of late infections, between 4 months and 2 years after MSC treatment. No increase in leukemia relapse or graft rejection was found. Children had a better survival rate than adults (P = .005). In GVHD patients, 1-year survival was 75% in patients who received early-passage MSCs (from passages 1-2) in contrast to 21% using later passage MSCs (from passages 3-4) (P < .01). We conclude that treatment with early-passage MSCs improved survival in patients with therapy-resistant GVHD. Death from infection was common in MSC-treated patients, but there was no increase in leukemia relapse. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
48. Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study
- Author
-
Remberger, Mats, Ackefors, Malin, Berglund, Sofia, Blennow, Ola, Dahllöf, Göran, Dlugosz, Aldona, Garming-Legert, Karin, Gertow, Jens, Gustafsson, Britt, Hassan, Moustapha, Hassan, Zuzana, Hauzenberger, Dan, Hägglund, Hans, Karlsson, Helen, Klingspor, Lena, Kumlien, Gunilla, Le Blanc, Katarina, Ljungman, Per, Machaczka, Maciej, and Malmberg, Karl-Johan
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *GRAFT versus host disease , *HEALTH outcome assessment , *CANCER treatment , *HEMATOLOGY , *GRANULOCYTE-colony stimulating factor , *T cells , *MULTIVARIATE analysis - Abstract
We analyzed the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) over the past 2 decades. Between 1992 and 2009, 953 patients were treated with HSCT, mainly for a hematologic malignancy. They were divided according to 4 different time periods of treatment: 1992 to 1995, 1996 to 2000, 2001 to 2005, and 2006 to 2009. Over the years, many factors have changed considerably regarding patient age, diagnosis, disease stage, type of donor, stem cell source, genomic HLA typing, cell dose, type of conditioning, treatment of infections, use of granulocyte-colony stimulating factor (G-CSF), use of mesenchymal stem cells, use of cytotoxic T cells, and home care. When we compared the last period (2006-2009) with earlier periods, we found slower neutrophil engraftment, a higher incidence of acute graft-versus-host disease (aGVHD) of grades II-IV, and less chronic GVHD (cGHVD). The incidence of relapse was unchanged over the 4 periods (22%-25%). Overall survival (OS) and transplant-related mortality (TRM) improved significantly in the more recent periods, with the best results during the last period (2006-2009) and a 100-day TRM of 5.5%. This improvement was also apparent in a multivariate analysis. When correcting for differences between the 4 groups, the hazard ratio for mortality in the last period was 0.59 (95% confidence interval [CI]: 0.44-0.79; P < .001) and for TRM it was 0.63 (CI: 0.43-0.92; P = .02). This study shows that the combined efforts to improve outcome after HSCT have been very effective. Even though we now treat older patients with more advanced disease and use more alternative HLA nonidentical donors, OS and TRM have improved. The problem of relapse still has to be remedied. Thus, several different developments together have resulted in significantly lower TRM and improved survival after HSCT over the last few years. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
49. Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions
- Author
-
Sairafi, Darius, Remberger, Mats, Uhlin, Michael, Ljungman, Per, Ringdén, Olle, and Mattsson, Jonas
- Subjects
- *
LEUKEMIA , *CELL lines , *MOSAICISM , *LYMPHOCYTES , *RETROSPECTIVE studies , *HEALTH outcome assessment , *HEMATOLOGY - Abstract
A retrospective analysis was performed of 118 patients with hematologic malignancies who received donor lymphocyte infusions (DLIs) after allogeneic stem cell transplantation (ASCT). Treatment was either given because of hematologic relapse (n = 44), molecular/cytogenetic relapse (n = 52), or other causes (n = 22). Molecular relapse was in most cases based on leukemia lineage-specific chimerism analysis. Patients with acute leukemia and myelodysplastic syndrome showed a 3-year survival of 42% if DLI treatment was given because of molecular relapse, compared to 16% in hematologic relapse (P < .006). In multivariate analysis, there was a correlation between response to DLI and nonhematologic relapse (risk ratio [RR] 3.36, P = .001), chronic graft-versus-host disease (cGVHD) (RR = 1.51, P = .005), and late relapse (RR = 2.06, P = .017). The overall incidences of acute GVHD (aGVHD) grades I-II and grades III-IV aGVHD were 33% and 8.5%, respectively. Probability of cGVHD was 33%. The development of aGVHD or cGVHD did not significantly influence the response of DLI in patients with molecular/cytogenetic relapse. However, the development of cGVHD was significantly associated with a better response in patients with hematologic relapse because only 4 of 29 patients without cGVHD responded compared to 7 of 12 with cGVHD (P = .007). The development of cGVHD increased significantly if DLI was given >12 months after ASCT (46% versus 27%, P = .04). In contrast, time between ASCT and start of DLI treatment had no significant influence on the risk of developing aGVHD. To conclude, monitoring of leukemia lineage-specific chimerism is of utmost importance for DLI response after ASCT. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
50. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: Results from the EBMT IDWP01 trial
- Author
-
Cordonnier, Catherine, Labopin, Myriam, Chesnel, Virginie, Ribaud, Patricia, Camara, Rafael De La, Martino, Rodrigo, Ullmann, Andrew J., Parkkali, Terttu, Locasciulli, Anna, Yakouben, Karima, Pauksens, Karlis, Bonnet, Eric, Einsele, Hermann, Niederwieser, Dietger, Apperley, Jane, and Ljungman, Per
- Subjects
- *
PNEUMOCOCCAL vaccines , *IMMUNE response , *POLYSACCHARIDES , *HOMOGRAFTS , *STEM cell transplantation , *SEROTYPES , *STREPTOCOCCUS pneumoniae , *VIRAL vaccines , *CLINICAL trials - Abstract
Abstract: The current recommendations for active immunization after stem cell transplant (SCT) include 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7) from 3 months after transplant, followed by a 23-valent polysaccharide pneumococcal vaccine (PPV23). However, until now, the immune response to PPV23 after PCV7 has not been assessed after SCT. In the EBMT IDWP01 trial, 101 patients received 1 dose of PPV23 at 12 or 18 months, both after 3 doses of PCV7. The efficacy of PPV23 was assessed 1 month later and at 24 months after transplant by the pneumococcal serotype 1 and 5 antibody levels. Serotype 1 and 5 are not included in PCV7. Although the geometric mean concentrations were significantly higher 1 month after PPV23, for both antigens, the response rates (≥0.15μg/mL), in the range of 68–94%, were not different between groups independent of the assessment date. One PPV23 dose after 3 PCV7 doses, already known to increase the response to PCV7, also extends the serotype coverage given 12 or 18 months after transplant. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.